# A Pharmacokinetics, Safety and Tolerability Study of Multiple Formulations of BMS-986231 in Healthy Participants

> **NCT03891108** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 60 (actual)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** BMS-986231 Formulation A
- **DRUG:** BMS-986231 Formulation B
- **DRUG:** BMS-986231 Formulation C
- **DRUG:** BMS-986231 Formulation D

## Key facts

- **NCT ID:** NCT03891108
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-28
- **Primary completion:** 2019-07-29
- **Final completion:** 2019-07-29
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2019-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03891108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03891108, "A Pharmacokinetics, Safety and Tolerability Study of Multiple Formulations of BMS-986231 in Healthy Participants". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03891108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*